First Time Loading...

Geron Corp
NASDAQ:GERN

Watchlist Manager
Geron Corp Logo
Geron Corp
NASDAQ:GERN
Watchlist
Price: 3.805 USD 6.88% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

Geron Corp. operates as a biotechnology company. [ Read More ]

The intrinsic value of one GERN stock under the Base Case scenario is 10.708 USD. Compared to the current market price of 3.805 USD, Geron Corp is Undervalued by 64%.

Key Points:
GERN Intrinsic Value
Base Case
10.708 USD
Undervaluation 64%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Geron Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GERN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Geron Corp

Provide an overview of the primary business activities
of Geron Corp.

What unique competitive advantages
does Geron Corp hold over its rivals?

What risks and challenges
does Geron Corp face in the near future?

Has there been any significant insider trading activity
in Geron Corp recently?

Summarize the latest earnings call
of Geron Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Geron Corp.

Provide P/S
for Geron Corp.

Provide P/E
for Geron Corp.

Provide P/OCF
for Geron Corp.

Provide P/FCFE
for Geron Corp.

Provide P/B
for Geron Corp.

Provide EV/S
for Geron Corp.

Provide EV/GP
for Geron Corp.

Provide EV/EBITDA
for Geron Corp.

Provide EV/EBIT
for Geron Corp.

Provide EV/OCF
for Geron Corp.

Provide EV/FCFF
for Geron Corp.

Provide EV/IC
for Geron Corp.

Show me price targets
for Geron Corp made by professional analysts.

What are the Revenue projections
for Geron Corp?

How accurate were the past Revenue estimates
for Geron Corp?

What are the Net Income projections
for Geron Corp?

How accurate were the past Net Income estimates
for Geron Corp?

What are the EPS projections
for Geron Corp?

How accurate were the past EPS estimates
for Geron Corp?

What are the EBIT projections
for Geron Corp?

How accurate were the past EBIT estimates
for Geron Corp?

Compare the revenue forecasts
for Geron Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Geron Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Geron Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Geron Corp compared to its peers.

Compare the P/E ratios
of Geron Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Geron Corp with its peers.

Analyze the financial leverage
of Geron Corp compared to its main competitors.

Show all profitability ratios
for Geron Corp.

Provide ROE
for Geron Corp.

Provide ROA
for Geron Corp.

Provide ROIC
for Geron Corp.

Provide ROCE
for Geron Corp.

Provide Gross Margin
for Geron Corp.

Provide Operating Margin
for Geron Corp.

Provide Net Margin
for Geron Corp.

Provide FCF Margin
for Geron Corp.

Show all solvency ratios
for Geron Corp.

Provide D/E Ratio
for Geron Corp.

Provide D/A Ratio
for Geron Corp.

Provide Interest Coverage Ratio
for Geron Corp.

Provide Altman Z-Score Ratio
for Geron Corp.

Provide Quick Ratio
for Geron Corp.

Provide Current Ratio
for Geron Corp.

Provide Cash Ratio
for Geron Corp.

What is the historical Revenue growth
over the last 5 years for Geron Corp?

What is the historical Net Income growth
over the last 5 years for Geron Corp?

What is the current Free Cash Flow
of Geron Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Geron Corp.

Financials

Balance Sheet Decomposition
Geron Corp

Current Assets 341.3m
Cash & Short-Term Investments 333.7m
Receivables 1.7m
Other Current Assets 6m
Non-Current Assets 52.7m
Long-Term Investments 43.3m
PP&E 4.7m
Other Non-Current Assets 4.7m
Current Liabilities 108.1m
Accounts Payable 6.2m
Accrued Liabilities 55m
Other Current Liabilities 46.9m
Non-Current Liabilities 38.1m
Long-Term Debt 35.1m
Other Non-Current Liabilities 3m
Efficiency

Earnings Waterfall
Geron Corp

Revenue
237k USD
Operating Expenses
-194.2m USD
Operating Income
-193.9m USD
Other Expenses
9.8m USD
Net Income
-184.1m USD

Free Cash Flow Analysis
Geron Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

GERN Profitability Score
Profitability Due Diligence

Geron Corp's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROE
17/100
Profitability
Score

Geron Corp's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

GERN Solvency Score
Solvency Due Diligence

Geron Corp's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
62/100
Solvency
Score

Geron Corp's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GERN Price Targets Summary
Geron Corp

Wall Street analysts forecast GERN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GERN is 5.185 USD with a low forecast of 4.545 USD and a high forecast of 6.3 USD.

Lowest
Price Target
4.545 USD
19% Upside
Average
Price Target
5.185 USD
36% Upside
Highest
Price Target
6.3 USD
66% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GERN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GERN Price
Geron Corp

1M 1M
+15%
6M 6M
+113%
1Y 1Y
+60%
3Y 3Y
+157%
5Y 5Y
+102%
10Y 10Y
+110%
Annual Price Range
3.805
52w Low
1.74
52w High
3.805
Price Metrics
Average Annual Return 14.22%
Standard Deviation of Annual Returns 51.2%
Max Drawdown -53%
Shares Statistics
Market Capitalization 2.1B USD
Shares Outstanding 588 059 008
Percentage of Shares Shorted 7.98%

GERN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Geron Corp Logo
Geron Corp

Country

United States of America

Industry

Biotechnology

Market Cap

2.1B USD

Dividend Yield

0%

Description

Geron Corp. operates as a biotechnology company. The company is headquartered in Foster City, California and currently employs 69 full-time employees. The firm operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).The Company has completed the evaluation of safety, tolerability, pharmacokinetics and pharmacodynamic effects of Imetelstat in its Phase I trials.

Contact

CALIFORNIA
Foster City
919 East Hillsdale Boulevard, Suite 250
+16504737700.0
http://www.geron.com/

IPO

1996-07-31

Employees

69

Officers

Chairman of the Board, President & CEO
Dr. John A. Scarlett M.D.
Executive VP & COO
Dr. Andrew J. Grethlein Ph.D.
Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
Ms. Michelle J. Robertson
Vice President of Investor Relations & Corporate Communications
Ms. Aron Feingold
Executive VP, Chief Legal Officer & Corporate Secretary
Mr. Scott Samuels
Senior VP & Chief People Officer
Ms. Shannon Odam
Show More
Executive VP of Business Operations & Chief Alliance Officer
Ms. Melissa A. Kelly Behrs
Executive VP of Corporate Strategy & Chief Commercial Officer
Mr. Anil Kapur
Executive VP & Chief Business Officer
Mr. Edward E. Koval
Executive VP & Chief Medical Officer
Dr. Faye Feller M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one GERN stock?

The intrinsic value of one GERN stock under the Base Case scenario is 10.708 USD.

Is GERN stock undervalued or overvalued?

Compared to the current market price of 3.805 USD, Geron Corp is Undervalued by 64%.